Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea

• DOI: 10.1016/j.jgar.2021.12.005
• Publication Date: 2021-12-14T17:29:44Z
• Authors: Yunjung Lee; Soo Sung Kim; Su-Mi Choi; Chan-Joong Bae; Tae-Hoon Oh; Seong Eun Kim; Uh Jin Kim; Seung-Ji Kang; Sook-In Jung; Kyung-Hwa Park
• Keywords: rpoB; Rifamycin; Rifabutin; Broth microdilution

We conducted an in vitro investigation of the activity rifamycins against planktonic and biofilm states Staphylococcus aureus epidermidis isolates from patients with prosthetic joint infections (PJIs), characterised their rpoB gene mutations, analysed clinical outcomes rifampicin-resistant isolates.A total 110 staphylococcal were collected PJI. Antimicrobials tested using broth microdilution method included rifampicin, rifabutin, rifapentine rifaximin. evaluated mutations to identify rifampicin resistance mechanisms. Clinical assessed isolates.The 85 S. (55% methicillin-resistant) 25 (100% methicillin-resistant). Seven two resistant [minimum inhibitory concentration (MIC) ≥2 μg/mL] these exhibited mutations. Among 78 rifampicin-susceptible 23 isolates, 76 (97.4%) all (100%) highly susceptible (MIC ≤ 0.06 μg/mL) other rifamycins. The minimum bactericidal concentrations for ≥50% (MBBC50) rifaximin 4, 1, 2 4 μg/mL 0.125, 0.25 0.5 epidermidis, respectively, among isolates. nine bearing only three (33%) had successful outcomes.Rifamycins than show promising antistaphylococcal activity, including antibiofilm activity. Rifamycin-resistant staphylococci exhibit